Clinical Trial Update: A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and expansion study of XL495 in locally advanced or metastatic solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Pelvis Urothelial Cancer
• Solid Tumor
• Solid Tumors
• Urothelial Cancer

Drugs mentioned

• XL495

Snippet

Sponsor: Exelixis | Conditions: Solid Cancers, Solid Tumor Cancer | Phase 1 | Status: TERMINATED